Pimozide (Orap) in patients with pseudo-neurotic behaviour.
Pimozide 2-12 mg (median 4 mg) was tried for ten weeks in 44 pseudo-neurotic patients. Unsuccessfully used tranquillizers were continued and the use of the antiparkinsonian agent dexetimide was allowed if needed. By the end of the study, a considerable improvement was observed for the vast majority of the items of the Wittenborn psychiatric scale. Their socio-professional adaptation showed a similar tendency. Dexetimide was required in four patients who received high doses of pimozide.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*; D010554:Personality Disorders / Q000188:drug therapy*; D010868:Pimozide / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D010868:Pimozide